Alterity Therapeutics Toekomstige groei
Future criteriumcontroles 2/6
Alterity Therapeutics's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 25% per year.
Belangrijke informatie
-2.7%
Groei van de winst
n/a
Groei van de winst per aandeel
Biotechs winstgroei | 27.1% |
Inkomstengroei | 25.0% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 29 Aug 2024 |
Recente toekomstige groei-updates
Geen updates
Recent updates
Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK
Aug 25Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy
Jul 06Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology
Sep 16Alterity Therapeutics names Dr. David Stamler as CEO
Jan 07Alterity and UniQuest partner to reverse bacterial resistance to antibiotics
Dec 21Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders
Nov 16Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
6/30/2026 | 7 | -20 | N/A | -20 | 1 |
6/30/2025 | 9 | -18 | -8 | -18 | 1 |
6/30/2024 | 4 | -19 | -13 | -13 | N/A |
3/31/2024 | 4 | -16 | -14 | -14 | N/A |
12/31/2023 | 3 | -12 | -15 | -15 | N/A |
9/30/2023 | 4 | -13 | -17 | -17 | N/A |
6/30/2023 | 4 | -14 | -20 | -20 | N/A |
3/31/2023 | 5 | -14 | -17 | -17 | N/A |
12/31/2022 | 5 | -14 | -14 | -14 | N/A |
9/30/2022 | 5 | -14 | -13 | -13 | N/A |
6/30/2022 | 5 | -13 | -12 | -12 | N/A |
3/31/2022 | 5 | -13 | -16 | -16 | N/A |
12/31/2021 | 5 | -13 | -19 | -19 | N/A |
9/30/2021 | 5 | -14 | -18 | -18 | N/A |
6/30/2021 | 4 | -15 | -17 | -17 | N/A |
3/31/2021 | 2 | -16 | -16 | -16 | N/A |
12/31/2020 | 0 | -16 | -14 | -14 | N/A |
9/30/2020 | 0 | -15 | -12 | -12 | N/A |
6/30/2020 | N/A | -13 | -9 | -9 | N/A |
3/31/2020 | 2 | -13 | -9 | -9 | N/A |
12/31/2019 | 4 | -13 | -9 | -9 | N/A |
9/30/2019 | 5 | -12 | -12 | -12 | N/A |
6/30/2019 | 5 | -12 | -14 | -14 | N/A |
3/31/2019 | 5 | -11 | -13 | -13 | N/A |
12/31/2018 | 4 | -10 | -12 | -12 | N/A |
9/30/2018 | 4 | -9 | -9 | -9 | N/A |
6/30/2018 | 3 | -8 | -6 | -6 | N/A |
3/31/2018 | 3 | -8 | N/A | -6 | N/A |
12/31/2017 | 3 | -8 | N/A | -6 | N/A |
9/30/2017 | 3 | -8 | N/A | -6 | N/A |
6/30/2017 | 3 | -8 | N/A | -6 | N/A |
3/31/2017 | 4 | -8 | N/A | -3 | N/A |
12/31/2016 | 4 | -9 | N/A | -1 | N/A |
9/30/2016 | 4 | -8 | N/A | -4 | N/A |
6/30/2016 | 5 | -8 | N/A | -7 | N/A |
3/31/2016 | 5 | -8 | N/A | -9 | N/A |
12/31/2015 | 6 | -7 | N/A | -10 | N/A |
9/30/2015 | 6 | -7 | N/A | -10 | N/A |
6/30/2015 | 6 | -6 | N/A | -11 | N/A |
3/31/2015 | 8 | -6 | N/A | -13 | N/A |
12/31/2014 | 10 | -7 | N/A | -15 | N/A |
9/30/2014 | 9 | -10 | N/A | -14 | N/A |
6/30/2014 | 8 | -13 | N/A | -14 | N/A |
3/31/2014 | 6 | -12 | N/A | -12 | N/A |
12/31/2013 | 4 | -11 | N/A | -11 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: ATHE is forecast to remain unprofitable over the next 3 years.
Winst versus markt: ATHE is forecast to remain unprofitable over the next 3 years.
Hoge groeiwinsten: ATHE is forecast to remain unprofitable over the next 3 years.
Omzet versus markt: ATHE's revenue (25% per year) is forecast to grow faster than the US market (8.9% per year).
Hoge groei-inkomsten: ATHE's revenue (25% per year) is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if ATHE's Return on Equity is forecast to be high in 3 years time